RNS & Investor News

Directorate Change

23 October 2024

OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024.

David Blain will join the Company as acting Finance Director on 1 November 2024. Mr Blain's appointment to the Board of the Company will be subject to normal regulatory due diligence.

David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.

The Company notes recent speculation in relation to the health of the Company's Chief Executive Officer Stephen O'Hara.  Mr O'Hara is recovering after a short illness and expects to be back at work shortly.

Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like to thank Graham for his contribution to the Company over the last year and welcome David as we move to our next stage of growth."

 

For further information, please contact: OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive


 


Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti


 


Peterhouse Capital Limited (Broker)

Tel: 020 7220 9797

Duncan Vasey / Lucy Williams




Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.